Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) Net Margin: 2015-2023

Historic Net Margin for Spyre Therapeutics (SYRE) over the last 5 years, with Jun 2023 value amounting to -31,552.47%.

  • Spyre Therapeutics' Net Margin fell 2798079.00% to -31,552.47% in Q2 2023 from the same period last year, while for Jun 2023 it was -22,195.36%, marking a year-over-year decrease of 2169901.00%. This contributed to the annual value of -38,238.15% for FY2023, which is 3463939.00% down from last year.
  • Spyre Therapeutics' Net Margin amounted to -31,552.47% in Q2 2023, which was down 239.13% from -9,304.04% recorded in Q1 2023.
  • Over the past 5 years, Spyre Therapeutics' Net Margin peaked at -151.82% during Q2 2021, and registered a low of -31,552.47% during Q2 2023.
  • Its 3-year average for Net Margin is -7,643.04%, with a median of -3,571.68% in 2022.
  • Data for Spyre Therapeutics' Net Margin shows a maximum YoY crashed of 2,798,079bps (in 2023) over the last 5 years.
  • Over the past 3 years, Spyre Therapeutics' Net Margin (Quarterly) stood at -561.09% in 2021, then crashed by 1,064,248bps to -11,203.57% in 2022, then plummeted by 2,798,079bps to -31,552.47% in 2023.
  • Its last three reported values are -31,552.47% in Q2 2023, -9,304.04% for Q1 2023, and -11,203.57% during Q4 2022.